{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T14:57:04Z","timestamp":1780066624382,"version":"3.54.0"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"25","license":[{"start":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T00:00:00Z","timestamp":1378080000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T00:00:00Z","timestamp":1378080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2014,6,19]]},"DOI":"10.1038\/onc.2013.291","type":"journal-article","created":{"date-parts":[[2013,9,2]],"date-time":"2013-09-02T10:19:23Z","timestamp":1378117163000},"page":"3307-3315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Therapeutic implications of activation of the host gene (Dleu2) promoter for miR-15a\/16-1 in chronic lymphocytic leukemia"],"prefix":"10.1038","volume":"33","author":[{"given":"S","family":"Kasar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Underbayev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Hanlon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Batish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Gavrilova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F","family":"Badiane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Degheidy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Marti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Raveche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,2]]},"reference":[{"key":"BFonc2013291_CR1","doi-asserted-by":"publisher","first-page":"5019","DOI":"10.1182\/blood-2011-01-293050","volume":"117","author":"E Campo","year":"2011","unstructured":"Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES . The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011; 117: 5019\u20135032.","journal-title":"Blood"},{"key":"BFonc2013291_CR2","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1046\/j.1365-2141.2001.02411.x","volume":"112","author":"G Piller","year":"2001","unstructured":"Piller G . Leukaemia\u2014a brief historical review from ancient times to 1950. Br J Haematol 2001; 112: 282\u2013292.","journal-title":"Br J Haematol"},{"key":"BFonc2013291_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1182\/blood-2008-05-155721","volume":"112","author":"E Montserrat","year":"2008","unstructured":"Montserrat E . Further progress in CLL therapy. Blood 2008; 112: 924\u2013925.","journal-title":"Blood"},{"key":"BFonc2013291_CR4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1182\/blood.V80.1.29.29","volume":"80","author":"LE Robertson","year":"1992","unstructured":"Robertson LE, Huh YO, Butler JJ, Pugh WC, Hirsch-Ginsberg C, Stass S et al. Response assessment in chronic lymphocytic leukemia after fludarabine plus prednisone: clinical, pathologic, immunophenotypic, and molecular analysis. Blood 1992; 80: 29\u201336.","journal-title":"Blood"},{"key":"BFonc2013291_CR5","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2011.36.9348","volume":"30","author":"S Bottcher","year":"2012","unstructured":"Bottcher S, Ritgen M, Fischer K, Stilgenbauer S, Busch RM, Fingerle-Rowson G et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 2012; 30: 980\u2013988.","journal-title":"J Clin Oncol"},{"key":"BFonc2013291_CR6","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/nrc3166","volume":"11","author":"AL Kasinski","year":"2011","unstructured":"Kasinski AL, Slack FJ . Epigenetics and genetics. MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nat Rev Cancer 2011; 11: 849\u2013864.","journal-title":"Nat Rev Cancer"},{"key":"BFonc2013291_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/gene.2011.58","volume":"13","author":"S Kasar","year":"2012","unstructured":"Kasar S, Salerno E, Yuan Y, Underbayev C, Vollenweider D, Laurindo MF et al. Systemic in vivo lentiviral delivery of miR-15a\/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia. Genes Immun 2012; 13: 109\u2013119.","journal-title":"Genes Immun"},{"key":"BFonc2013291_CR8","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","volume":"343","author":"H Dohner","year":"2000","unstructured":"Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910\u20131916.","journal-title":"N Engl J Med"},{"key":"BFonc2013291_CR9","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1080\/10428190310001638832","volume":"45","author":"H Chang","year":"2004","unstructured":"Chang H, Li D, Zhuang L, Nie E, Bouman D, Stewart AK et al. Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: comparison with karyotype analysis. Leuk Lymphoma 2004; 45: 965\u2013969.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2013291_CR10","first-page":"116","volume":"29","author":"L Chen","year":"2007","unstructured":"Chen L, Li J, Xu W, Qiu H, Zhu Y, Zhang Y et al. Molecular cytogenetic aberrations in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol 2007; 29: 116\u2013120.","journal-title":"Exp Oncol"},{"key":"BFonc2013291_CR11","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.leukres.2006.10.022","volume":"31","author":"E Flordal Thelander","year":"2007","unstructured":"Flordal Thelander E, Ichimura K, Collins VP, Walsh SH, Barbany G, Hagberg A et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007; 31: 1219\u20131230.","journal-title":"Leuk Res"},{"key":"BFonc2013291_CR12","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1182\/blood.V91.4.1382","volume":"91","author":"MM Corcoran","year":"1998","unstructured":"Corcoran MM, Rasool O, Liu Y, Iyengar A, Grander D, Ibbotson RE et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood 1998; 91: 1382\u20131390.","journal-title":"Blood"},{"key":"BFonc2013291_CR13","doi-asserted-by":"publisher","first-page":"2098","DOI":"10.1182\/blood.V97.7.2098","volume":"97","author":"A Migliazza","year":"2001","unstructured":"Migliazza A, Bosch F, Komatsu H, Cayanis E, Martinotti S, Toniato E et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098\u20132104.","journal-title":"Blood"},{"key":"BFonc2013291_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","volume":"17","author":"U Klein","year":"2010","unstructured":"Klein U, Lia M, Crespo M, Siegel R, Shen Q, Mo T et al. The DLEU2\/miR-15a\/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010; 17: 28\u201340.","journal-title":"Cancer Cell"},{"key":"BFonc2013291_CR15","doi-asserted-by":"publisher","first-page":"3916","DOI":"10.1182\/blood-2009-10-249367","volume":"115","author":"A Palamarchuk","year":"2010","unstructured":"Palamarchuk A, Efanov A, Nazaryan N, Santanam U, Alder H, Rassenti L et al. 13q14 Deletions in CLL involve cooperating tumor suppressors. Blood 2010; 115: 3916\u20133922.","journal-title":"Blood"},{"key":"BFonc2013291_CR16","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1101\/gr.2722704","volume":"14","author":"A Rodriguez","year":"2004","unstructured":"Rodriguez A, Griffiths-Jones S, Ashurst JL, Bradley A . Identification of mammalian microRNA host genes and transcription units. Genome Res 2004; 14: 1902\u20131910.","journal-title":"Genome Res"},{"issue":"Suppl 1","key":"BFonc2013291_CR17","doi-asserted-by":"publisher","first-page":"S98","DOI":"10.1002\/cyto.b.20544","volume":"78","author":"E Salerno","year":"2010","unstructured":"Salerno E, Yuan Y, Scaglione BJ, Marti G, Jankovic A, Mazzella F et al. The New Zealand black mouse as a model for the development and progression of chronic lymphocytic leukemia. Cytometry B 2010; 78 (Suppl 1): S98\u2013S109.","journal-title":"Cytometry B"},{"key":"BFonc2013291_CR18","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1182\/blood-2007-02-071225","volume":"109","author":"ES Raveche","year":"2007","unstructured":"Raveche ES, Salerno E, Scaglione BJ, Manohar V, Abbasi F, Lin YC et al. Abnormal microRNA-16 locus with synteny to human 13q14 linked to CLL in NZB mice. Blood 2007; 109: 5079\u20135086.","journal-title":"Blood"},{"key":"BFonc2013291_CR19","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa050995","volume":"353","author":"GA Calin","year":"2005","unstructured":"Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE et al. A microRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793\u20131801.","journal-title":"N Engl J Med"},{"key":"BFonc2013291_CR20","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1158\/1535-7163.MCT-09-0127","volume":"8","author":"E Salerno","year":"2009","unstructured":"Salerno E, Scaglione BJ, Coffman FD, Brown BD, Baccarini A, Fernandes H et al. Correcting miR-15a\/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol Cancer Ther 2009; 8: 2684\u20132692.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2013291_CR21","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.4161\/cbt.7.11.6722","volume":"7","author":"EY Chung","year":"2008","unstructured":"Chung EY, Dews M, Cozma D, Yu D, Wentzel EA, Chang TC et al. c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther 2008; 7: 1758\u20131764.","journal-title":"Cancer Biol Ther"},{"key":"BFonc2013291_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/B978-0-12-385991-4.00005-2","volume":"111","author":"J Medvedovic","year":"2011","unstructured":"Medvedovic J, Ebert A, Tagoh H, Busslinger M . Pax5: a master regulator of B cell development and leukemogenesis. Adv Immunol 2011; 111: 179\u2013206.","journal-title":"Adv Immunol"},{"key":"BFonc2013291_CR23","doi-asserted-by":"publisher","first-page":"7345","DOI":"10.1158\/0008-5472.CAN-11-1874","volume":"71","author":"P O'Brien","year":"2011","unstructured":"O'Brien P, Morin P Jr., Ouellette RJ, Robichaud GA . The Pax-5 gene: a pluripotent regulator of B-cell differentiation and cancer disease. Cancer Res 2011; 71: 7345\u20137350.","journal-title":"Cancer Res"},{"key":"BFonc2013291_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.leukres.2011.07.017","volume":"36","author":"S Firtina","year":"2012","unstructured":"Firtina S, Sayitoglu M, Hatirnaz O, Erbilgin Y, Oztunc C, Cinar S et al. Evaluation of PAX5 gene in the early stages of leukemic B cells in the childhood B cell acute lymphoblastic leukemia. Leuk Res 2012; 36: 87\u201392.","journal-title":"Leuk Res"},{"key":"BFonc2013291_CR25","doi-asserted-by":"publisher","first-page":"4609","DOI":"10.1093\/nar\/gkn432","volume":"36","author":"GA Robichaud","year":"2008","unstructured":"Robichaud GA, Perreault JP, Ouellette RJ . Development of an isoform-specific gene suppression system: the study of the human Pax-5B transcriptional element. Nucleic Acids Res 2008; 36: 4609\u20134620.","journal-title":"Nucleic Acids Res"},{"key":"BFonc2013291_CR26","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1093\/jnci\/djr246","volume":"103","author":"RW Humphrey","year":"2011","unstructured":"Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, Doroshow JH, Meech SJ et al. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst 2011; 103: 1222\u20131226.","journal-title":"J Natl Cancer Inst"},{"key":"BFonc2013291_CR27","doi-asserted-by":"publisher","first-page":"e7169","DOI":"10.1371\/journal.pone.0007169","volume":"4","author":"K Hanlon","year":"2009","unstructured":"Hanlon K, Rudin CE, Harries LW . Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). PLoS One 2009; 4: e7169.","journal-title":"PLoS One"},{"key":"BFonc2013291_CR28","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1046\/j.1365-2141.1998.00842.x","volume":"102","author":"T Hamada","year":"1998","unstructured":"Hamada T, Yonetani N, Ueda C, Maesako Y, Akasaka H, Akasaka T et al. Expression of the PAX5\/BSAP transcription factor in haematological tumour cells and further molecular characterization of the t(9;14) (p13;q32) translocation in B-cell non-Hodgkin's lymphoma. Br J Haematol 1998; 102: 691\u2013700.","journal-title":"Br J Haematol"},{"key":"BFonc2013291_CR29","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1182\/blood-2002-06-1797","volume":"101","author":"D Yu","year":"2003","unstructured":"Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, Thomas-Tikhonenko A . Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing\/reactivation of the EBF\/Pax5 pathway. Blood 2003; 101: 1950\u20131955.","journal-title":"Blood"},{"key":"BFonc2013291_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/j.1365-2141.2007.06851.x","volume":"139","author":"BJ Scaglione","year":"2007","unstructured":"Scaglione BJ, Salerno E, Balan M, Coffman F, Landgraf P, Abbasi F et al. Murine models of chronic lymphocytic leukaemia: role of microRNA-16 in the New Zealand Black mouse model. Br J Haematol 2007; 139: 645\u2013657.","journal-title":"Br J Haematol"},{"key":"BFonc2013291_CR31","doi-asserted-by":"publisher","first-page":"13944","DOI":"10.1073\/pnas.0506654102","volume":"102","author":"A Cimmino","year":"2005","unstructured":"Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M et al. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944\u201313949.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013291_CR32","doi-asserted-by":"publisher","first-page":"5166","DOI":"10.1073\/pnas.0800121105","volume":"105","author":"GA Calin","year":"2008","unstructured":"Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci USA 2008; 105: 5166\u20135171.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013291_CR33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/ng.2007.30","volume":"40","author":"TC Chang","year":"2008","unstructured":"Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 2008; 40: 43\u201350.","journal-title":"Nat Genet"},{"key":"BFonc2013291_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1182\/blood-2008-01-136218","volume":"113","author":"H Zhao","year":"2009","unstructured":"Zhao H, Kalota A, Jin S, Gewirtz AM . The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood 2009; 113: 505\u2013516.","journal-title":"Blood"},{"key":"BFonc2013291_CR35","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1038\/ni1454","volume":"8","author":"C Cobaleda","year":"2007","unstructured":"Cobaleda C, Schebesta A, Delogu A, Busslinger M . Pax5: the guardian of B cell identity and function. Nat Immunol 2007; 8: 463\u2013470.","journal-title":"Nat Immunol"},{"key":"BFonc2013291_CR36","doi-asserted-by":"publisher","first-page":"643","DOI":"10.2174\/187152011796817637","volume":"11","author":"N Crapoulet","year":"2011","unstructured":"Crapoulet N, O\u2019Brien P, Ouellette RJ, Robichaud GA . Coordinated expression of Pax-5 and FAK1 in metastasis. Anticancer Agents Med Chem 2011; 11: 643\u2013649.","journal-title":"Anticancer Agents Med Chem"},{"key":"BFonc2013291_CR37","first-page":"23","volume":"5","author":"M Zhang","year":"1998","unstructured":"Zhang M, Raveche ES . Apoptosis induction in fludarabine resistant malignant B-1 cells by G2\u2013M cell cycle arrest. Oncol Rep 1998; 5: 23\u201330.","journal-title":"Oncol Rep"},{"key":"BFonc2013291_CR38","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s002620000165","volume":"50","author":"SY Chong","year":"2001","unstructured":"Chong SY, Zhang M, Lin YC, Coffman F, Garcia Z, Ponzio N et al. The growth-regulatory role of B-cell-specific activator protein in NZB malignant B-1 cells. Cancer Immunol Immunother 2001; 50: 41\u201350.","journal-title":"Cancer Immunol Immunother"},{"key":"BFonc2013291_CR39","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1006\/excr.2000.5122","volume":"264","author":"M Zhang","year":"2001","unstructured":"Zhang M, Chong SY, Raveche ES . The role of B-cell-specific activator protein in the response of malignant B-1 cells to LPS. Exp Cell Res 2001; 264: 233\u2013243.","journal-title":"Exp Cell Res"},{"key":"BFonc2013291_CR40","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1093\/carcin\/bgh190","volume":"25","author":"FB Baumann Kubetzko","year":"2004","unstructured":"Baumann Kubetzko FB, Di Paolo C, Maag C, Meier R, Schafer BW, Betts DR et al. The PAX5 oncogene is expressed in N-type neuroblastoma cells and increases tumorigenicity of a S-type cell line. Carcinogenesis 2004; 25: 1839\u20131846.","journal-title":"Carcinogenesis"},{"key":"BFonc2013291_CR41","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s12185-010-0691-9","volume":"92","author":"M Proulx","year":"2010","unstructured":"Proulx M, Cayer MP, Drouin M, Laroche A, Jung D . Overexpression of PAX5 induces apoptosis in multiple myeloma cells. Int J Hematol 2010; 92: 451\u2013462.","journal-title":"Int J Hematol"},{"key":"BFonc2013291_CR42","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1182\/blood.V92.4.1308","volume":"92","author":"L Krenacs","year":"1998","unstructured":"Krenacs L, Himmelmann AW, Quintanilla-Martinez L, Fest T, Riva A, Wellmann A et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998; 92: 1308\u20131316.","journal-title":"Blood"},{"key":"BFonc2013291_CR43","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1002\/gcc.20214","volume":"44","author":"B Poppe","year":"2005","unstructured":"Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C et al. PAX5\/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements. Genes Chromosomes Cancer 2005; 44: 218\u2013223.","journal-title":"Genes Chromosomes Cancer"},{"key":"BFonc2013291_CR44","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/labinvest.2008.168","volume":"89","author":"R Kanteti","year":"2009","unstructured":"Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S et al. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest 2009; 89: 301\u2013314.","journal-title":"Lab Invest"},{"key":"BFonc2013291_CR45","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1172\/JCI45851","volume":"122","author":"EY Chung","year":"2012","unstructured":"Chung EY, Psathas JN, Yu D, Li Y, Weiss MJ, Thomas-Tikhonenko A . CD19 is a major B cell receptor-independent activator of MYC-driven B-lymphomagenesis. J Clin Invest 2012; 122: 2257\u20132266.","journal-title":"J Clin Invest"},{"key":"BFonc2013291_CR46","doi-asserted-by":"publisher","first-page":"15524","DOI":"10.1073\/pnas.242606799","volume":"99","author":"GA Calin","year":"2002","unstructured":"Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E et al. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524\u201315529.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013291_CR47","doi-asserted-by":"publisher","first-page":"3002","DOI":"10.1038\/onc.2011.470","volume":"31","author":"X Zhang","year":"2012","unstructured":"Zhang X, Chen X, Lin J, Lwin T, Wright G, Moscinski LC et al. Myc represses miR-15a\/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene 2012; 31: 3002\u20133008.","journal-title":"Oncogene"},{"key":"BFonc2013291_CR48","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1159\/000334577","volume":"81","author":"JC Wang","year":"2011","unstructured":"Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011; 81: 325\u2013329.","journal-title":"Oncology"},{"key":"BFonc2013291_CR49","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.4161\/epi.22674","volume":"7","author":"M Van Damme","year":"2012","unstructured":"Van Damme M, Crompot E, Meuleman N, Mineur P, Bron D, Lagneaux L et al. HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance. Epigenetics 2012; 7: 1403\u20131412.","journal-title":"Epigenetics"},{"key":"BFonc2013291_CR50","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.molonc.2012.07.003","volume":"6","author":"B Barneda-Zahonero","year":"2012","unstructured":"Barneda-Zahonero B, Parra M . Histone deacetylases and cancer. Mol Oncol 2012; 6: 579\u2013589.","journal-title":"Mol Oncol"},{"key":"BFonc2013291_CR51","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/icb.2011.100","volume":"90","author":"O Khan","year":"2012","unstructured":"Khan O, La Thangue NB . HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012; 90: 85\u201394.","journal-title":"Immunol Cell Biol"},{"key":"BFonc2013291_CR52","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/JTO.0b013e318191520c","volume":"4","author":"SS Ramalingam","year":"2009","unstructured":"Ramalingam SS, Belani CP, Ruel C, Frankel P, Gitlitz B, Koczywas M et al. Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma. J Thorac Oncol 2009; 4: 97\u2013101.","journal-title":"J Thorac Oncol"},{"key":"BFonc2013291_CR53","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1158\/1078-0432.CCR-10-1893","volume":"17","author":"A Stathis","year":"2011","unstructured":"Stathis A, Hotte SJ, Chen EX, Hirte HW, Oza AM, Moretto P et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin Cancer Res 2011; 17: 1582\u20131590.","journal-title":"Clin Cancer Res"},{"key":"BFonc2013291_CR54","doi-asserted-by":"publisher","first-page":"e10941","DOI":"10.1371\/journal.pone.0010941","volume":"5","author":"DM Lucas","year":"2010","unstructured":"Lucas DM, Alinari L, West DA, Davis ME, Edwards RB, Johnson AJ et al. The novel deacetylase inhibitor AR-42 demonstrates pre-clinical activity in B-cell malignancies in vitro and in vivo. PLoS One 2010; 5: e10941.","journal-title":"PLoS One"},{"key":"BFonc2013291_CR55","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1158\/1535-7163.MCT-09-1000","volume":"9","author":"V El-Khoury","year":"2010","unstructured":"El-Khoury V, Moussay E, Janji B, Palissot V, Aouali N, Brons NH et al. The histone deacetylase inhibitor MGCD0103 induces apoptosis in B-cell chronic lymphocytic leukemia cells through a mitochondria-mediated caspase activation cascade. Mol Cancer Ther 2010; 9: 1349\u20131360.","journal-title":"Mol Cancer Ther"},{"key":"BFonc2013291_CR56","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.leukres.2010.08.001","volume":"35","author":"JA Dubovsky","year":"2011","unstructured":"Dubovsky JA, Wang D, Powers JJ, Berchmans E, Smith MA, Wright KL et al. Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers. Leuk Res 2011; 35: 394\u2013404.","journal-title":"Leuk Res"},{"key":"BFonc2013291_CR57","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.4161\/epi.6.10.17200","volume":"6","author":"A Perez-Perarnau","year":"2011","unstructured":"Perez-Perarnau A, Coll-Mulet L, Rubio-Patino C, Iglesias-Serret D, Cosialls AM, Gonzalez-Girones DM et al. Analysis of apoptosis regulatory genes altered by histone deacetylase inhibitors in chronic lymphocytic leukemia cells. Epigenetics 2011; 6: 1228\u20131235.","journal-title":"Epigenetics"},{"key":"BFonc2013291_CR58","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1182\/blood-2011-05-351510","volume":"119","author":"D Sampath","year":"2012","unstructured":"Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG et al. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood 2012; 119: 1162\u20131172.","journal-title":"Blood"},{"key":"BFonc2013291_CR59","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/leu.2011.117","volume":"25","author":"MC Lanasa","year":"2011","unstructured":"Lanasa MC, Allgood SD, Slager SL, Dave SS, Love C, Marti GE et al. Immunophenotypic and gene expression analysis of monoclonal B-cell lymphocytosis shows biologic characteristics associated with good prognosis CLL. Leukemia 2011; 25: 1459\u20131466.","journal-title":"Leukemia"},{"key":"BFonc2013291_CR60","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1080\/10428190902763509","volume":"50","author":"D Mertens","year":"2009","unstructured":"Mertens D, Philippen A, Ruppel M, Allegra D, Bhattacharya N, Tschuch C et al. Chronic lymphocytic leukemia and 13q14: miRs and more. Leuk Lymphoma 2009; 50: 502\u2013505.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2013291_CR61","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/ng.2271","volume":"44","author":"CC Laurie","year":"2012","unstructured":"Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet 2012; 44: 642\u2013650.","journal-title":"Nat Genet"},{"key":"BFonc2013291_CR62","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.4049\/jimmunol.153.4.1869","volume":"153","author":"B Peng","year":"1994","unstructured":"Peng B, Sherr DH, Mahboudi F, Hardin J, Wu YH, Sharer L et al. A cultured malignant B-1 line serves as a model for Richter's syndrome. J Immunol 1994; 153: 1869\u20131880.","journal-title":"J Immunol"},{"key":"BFonc2013291_CR63","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/path.2620","volume":"220","author":"S Bougel","year":"2010","unstructured":"Bougel S, Renaud S, Braunschweig R, Loukinov D, Morse HC 3rd, Bosman FT et al. PAX5 activates the transcription of the human telomerase reverse transcriptase gene in B cells. J Pathol 2010; 220: 87\u201396.","journal-title":"J Pathol"},{"key":"BFonc2013291_CR64","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1756-8722-2-31","volume":"2","author":"D Siegel","year":"2009","unstructured":"Siegel D, Hussein M, Belani C, Robert F, Galanis E, Richon VM et al. Vorinostat in solid and hematologic malignancies. J Hematol Oncol 2009; 2: 31.","journal-title":"J Hematol Oncol"},{"key":"BFonc2013291_CR65","doi-asserted-by":"publisher","first-page":"4645","DOI":"10.1073\/pnas.1111226109","volume":"109","author":"M Batish","year":"2012","unstructured":"Batish M, van den Bogaard P, Kramer FR, Tyagi S . Neuronal mRNAs travel singly into dendrites. Proc Natl Acad Sci USA 2012; 109: 4645\u20134650.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2013291_CR66","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-61779-005-8_1","volume":"714","author":"M Batish","year":"2011","unstructured":"Batish M, Raj A, Tyagi S . Single molecule imaging of RNA in situ. Methods Mol Biol 2011; 714: 3\u201313.","journal-title":"Methods Mol Biol"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2013291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2013291","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2013291.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T07:44:10Z","timestamp":1688456650000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2013291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,2]]},"references-count":66,"journal-issue":{"issue":"25","published-print":{"date-parts":[[2014,6,19]]}},"alternative-id":["BFonc2013291"],"URL":"https:\/\/doi.org\/10.1038\/onc.2013.291","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,2]]},"assertion":[{"value":"12 December 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}